logo ecco

logo ecco

Portal
  • About ECCO
    • General Assembly
    • Governing Board
    • Committees / Operational Board
    • The Council of National Representatives
    • Collaborations
    • Solidarity for Ukraine
    • Elections
    • Community Videos
    • Affiliate Societies & Partners
    • Y-ECCO Contributors
    • ECCO Office
    • ECCO Disclosures
    • REACH
    • Diversity, Equity & Inclusion
  • Congresses & Events
    • Upcoming
      • 21st Congress of ECCO 2026 - Stockholm
    • Past
      • 20th Congress of ECCO 2025 - Berlin
      • 19th Congress of ECCO 2024 - Stockholm
    • Event Calendar
    • Congress Statistics
    • Quality Assurance/Endorsement
  • Membership
    • Individual Membership
    • Country Members
    • Corporate Membership
    • Affiliate ECCO Societies
  • Education
    • E-QUALITY
    • e-Learning
    • Letters from the e-Learning Editor-in-Chief
    • Educational Workshops
    • Congress Educational Programme
    • IBD Nurse Education Programme
    • Y-ECCO Mentorship Forum
    • Fast Facts in IBD
  • Science
    • UR-CARE
    • The Reviewers of ECCO
    • The Reviewers of 2024
    • Fellowships, Grants & Awards
    • ECCO Young Researcher Award
    • Scientific Workshops
    • Research Projects
    • ECCO CONFER Cases
  • Publications
    • JCC
    • JCC Plus
    • JCC on X/Twitter
    • Guidelines
    • Topical Review
    • Position Statements
    • Scientific Workshop Papers
    • ECCO News
    • ECCO IBD App
    • Congress Abstracts
    • Surveys
    • Other publications
    • eNewsletter

ECCO'25 Abstracts

ECCO'25 Abstracts on the JCC Website

ECCO'25 Abstract Book PDF Version

ECCO'25 Abstracts COI Disclosure

ECCO'24 Abstracts

ECCO'24 Abstracts on the JCC Website

ECCO'24 Abstract Book PDF Version

ECCO'24 Abstracts COI Disclosure

Poster Presentations: Clinical: Therapy and Observation 2023

P452 Fecal Microbiota Transplantation Leads to Lower IBD Related Complications in Hospitalized Inflammatory Bowel Disease Patients with Clostridioides difficile Infection: A retrospective cohort study

Le, P.H.(1)*;Chiu, C.H.(2);Chiu, C.T.(1);Kuo, C.J.(1);Yeh, P.J.(3);Chen, C.C.(3);Pan, Y.B.(4);

(1)Chang Gung Memorial Hospital- Linkou Branch, Department of Gastroenterology and Hepatology, Taoyuan, Taiwan;(2)Chang Gung Memorial Hospital, Chang Gung Microbiota Therapy Center, Taoyuan, Taiwan;(3)Chang Gung Memorial Hospital- Linkou Branch, Department of Pediatric Gastroenterology, Taoyuan, Taiwan;(4)Chang Gung Memorial Hospital- Linkou Branch, Biostatistical Section- Clinical Trial Center, Taoyuan, Taiwan;

Background

Clostridioides difficile (C. difficile) infection (CDI) increases the risks of hospitalization, colectomy, and mortality in inflammatory bowel disease (IBD). There has been no study comprehensively evaluating the risk factors, clinical characteristics, and outcomes of CDI in IBD.

Methods

In this retrospective cohort study, we enrolled hospitalized IBD patients with toxin A/B results for C. difficile in a medical center between April 2007 and April 2021. They were divided into CDI group and control groups. The risk factors, clinical presentations and outcomes were analyzed.

Results

A total of 144 IBD inpatients (45 CDI group and 99 control group) were enrolled for analysis. The median follow-up duration was 15.5 months. The incidence of CDI in IBD inpatients was 31%. The risk factors of CDI included longer IBD duration, biological failure, and biological user. More patients presented as abdominal pain in CDI group (77.8% vs 55.6%, P=0.011). After antibiotics treatment and fecal microbiota transplantation, 83.3% patients had negative result, and 61.9% had improved clinical symptoms. Regarding clinical outcomes, CDI led to more hospitalizations (median 2 times (range 0-12 times) vs median 1 time (range 0-19 times), P=0.008), lower steroid free remission rate (46.7% vs 67.7%, P=0.017) and higher Mayo score (median 5 points (range 2-12 points) vs median 3 points (range 0-12 points)). Compared to antibiotics treatment, the patients receiving fecal microbiota transplantation (FMT) had less times of hospitalization and less IBD related complications during follow-up.

Conclusion

CDI led to more hospitalizations, lower steroid free remission rate and higher Mayo score in IBD inpatients. FMT should be considered in refractory or recurrent CDI in IBD to improve the clinical outcomes.

  • Posted in: Poster Presentations: Clinical: Therapy and Observation 2023
Logo_contact.png     T: +43 (0)1 710 22 42-0
F: +43 (0)1 710 22 42-001
E: This email address is being protected from spambots. You need JavaScript enabled to view it.
  • Home
  • Sitemap
  • Contact
  • Imprint
  • Data privacy statement
  • Media Policy

  • About ECCO
    • General Assembly
    • Governing Board
    • Committees / Operational Board
    • The Council of National Representatives
    • Collaborations
    • Solidarity for Ukraine
    • Elections
    • Community Videos
    • Affiliate Societies & Partners
    • Y-ECCO Contributors
    • ECCO Office
    • ECCO Disclosures
    • REACH
    • Diversity, Equity & Inclusion
  • Congresses & Events
    • Upcoming
      • 21st Congress of ECCO 2026 - Stockholm
    • Past
      • 20th Congress of ECCO 2025 - Berlin
      • 19th Congress of ECCO 2024 - Stockholm
    • Event Calendar
    • Congress Statistics
    • Quality Assurance/Endorsement
  • Membership
    • Individual Membership
    • Country Members
    • Corporate Membership
    • Affiliate ECCO Societies
  • Education
    • E-QUALITY
    • e-Learning
    • Letters from the e-Learning Editor-in-Chief
    • Educational Workshops
    • Congress Educational Programme
    • IBD Nurse Education Programme
    • Y-ECCO Mentorship Forum
    • Fast Facts in IBD
  • Science
    • UR-CARE
    • The Reviewers of ECCO
    • The Reviewers of 2024
    • Fellowships, Grants & Awards
    • ECCO Young Researcher Award
    • Scientific Workshops
    • Research Projects
    • ECCO CONFER Cases
  • Publications
    • JCC
    • JCC Plus
    • JCC on X/Twitter
    • Guidelines
    • Topical Review
    • Position Statements
    • Scientific Workshop Papers
    • ECCO News
    • ECCO IBD App
    • Congress Abstracts
    • Surveys
    • Other publications
    • eNewsletter